Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: Weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history

E. Jabbour, A. Hochhaus, J. Cortes, P. La Rosée, H. M. Kantarjian

Research output: Contribution to journalReview articlepeer-review

65 Scopus citations

Fingerprint

Dive into the research topics of 'Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: Weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history'. Together they form a unique fingerprint.

Medicine & Life Sciences